Each year over 1,5 million man are suspected to have prostate cancer (PCa) based on an increased PSA (Prostate Specific Antigen) blood value. Each suspected patient is diagnosed whether the indication is actually true and what the stage of the PCa is. At present this diagnosis involves taking of 12 tissue biopts. Related problems with this method are: 6% infection risk, 40% false negatives and a 75% over- treatment rate.
Researchers at the Technical University of Eindhoven have developed a methodology and algorithms enabling to detect, localise and characterise prostate cancer tumors with ultrasound: PCaVision.
PCaVision can replace the biopsy based diagnosis eliminating infection risk, reducing cost and increasing patient comfort and outcomes.
Company’s Keywords:
14
medical devices
Google Cloud Hosting, Wix, Varnish, Mobile Friendly
2020
Your request has been submitted successfully.
Own or work here?